Visual contrast sensitivity (CS) impairment in patients with post treatment Lyme disease (PTLD) is linked to signs of cognitive and neurologic impairment and may be a marker of illness severity.
This report presents a Lyme disease case that was initially misdiagnosed in the spring of 2020 resulting in disseminated infection and sixth nerve palsy and highlights new challenges facing healthcare delivery in the era of COVID-19. The objective of this report is to describe the obstacles for diagnosticians during the pandemic and also to discuss the potential beneficial application of telemedicine in the early diagnosis of Lyme disease during the COVID-19 era as well as in the future.
The erythema migrans (EM) rash, when present, is often the first clinical sign of Lyme disease. This study shows that EM presentations vary with age, sex, EM duration, body location, and timing of initiation of antibiotics. Understanding this EM variability can help physicians and the general public better recognize the rash and improve early diagnosis and treatment.
This study examines heterogeneity in symptom reporting in patients with well-defined post treatment Lyme disease (PTLD) in order to identify and characterize clinically relevant patient subgroups.
Objective metabolite-based measurements differ between Lyme disease patients that develop persistent symptoms following antibiotic treatment (PTLD) and those that are clinically cured. These differences could be useful in better identifying, differentiating, and understanding the underlying biochemistry of patients with persistent symptoms in Lyme disease.
Lyme disease infection and genetic susceptibility to autoimmune diseases may trigger breakdown in tolerance to self-antigens & contribute to dysregulated immunity, autoimmune illness, & persistent symptoms
